# A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

> **NCT00991107** · PHASE1 · COMPLETED · sponsor: **Harbor Therapeutics** · enrollment: 5 (actual)

## Conditions studied

- Insulin Resistance

## Interventions

- **DRUG:** HE3286

## Key facts

- **NCT ID:** NCT00991107
- **Lead sponsor:** Harbor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2011-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991107, "A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00991107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*